Leukocytes: The Hidden Threats in Transfusion and the Lifesaving Role of Leukoreduction
Maxime Dely, Global Expert in Blood Processing & Therapeutic Apheresis, shared an insightful post on LinkedIn:
“Leukocytes: the invisible enemies of transfusion
I remember a patient we’ll call Laurent, 67 years old, who came in for a red blood cell transfusion due to severe anemia. Everything seemed under control… until two hours after the transfusion. Chills, sudden fever, blood pressure dropping.
On the surface, the blood unit looked perfect. Test results were normal. Yet an invisible culprit was there: leukocytes.
These white blood cells, vital allies in the donor’s body, can become real saboteurs in the recipient.
They can trigger:
- Febrile non-hemolytic transfusion reactions
- Alloimmunization that complicates future transfusions
- Unpredictable inflammatory reactions
This is where leukoreduction comes in: filtering the blood within hours after donation to remove more than 99.9% of these cells. A discreet step, but one that changes everything.
Since leukoreduction became standard practice in many transfusion systems, incidents like Laurent’s have become rare. But rare doesn’t mean impossible — and each case reminds us why this measure exists.
We’ve already discussed filtration in a previous article, but it’s important to remember that not all countries or organizations have the financial or equipments to access this technology.
In an upcoming article, we’ll see that centrifugation remains the first essential step toward leukoreduction, especially in settings with limited financial or material resources.
And you — do you think universal leukoreduction should be mandatory worldwide?”
Follow the newest insights in hematology with Hemostasis Today.
-
Sep 2, 2025, 08:51Perioperative Direct Oral Anticoagulant (DOAC) Dosing: Insights Dr. Sthanu Subramanian
-
Sep 2, 2025, 08:49Why Polycythemia Vera Doesn’t Raise EPO Levels Explained by William Aird
-
Sep 2, 2025, 08:47SUGAR Trial in Heart BMJ: Stent Outcomes in Patients With Diabetes Under the Spotlight
-
Sep 2, 2025, 08:43Eltrombopag with Immunosuppressive Therapy Shows Promising Safety in Pediatric Severe Aplastic Anemia – Phase 2 ESCALATE Trial Results
-
Sep 2, 2025, 08:14Mirvat Alasnag Discusses OPTION-STEMI Findings Published in The Lancet
-
Sep 1, 2025, 15:31Low-Dose DOACs Reduce VTE Risk in Transplant-Ineligible Multiple Myeloma: Insights from the BENEFIT Trial
-
Sep 1, 2025, 07:39Flora Peyvandi: Reappraising Hemostasis Testing in Cirrhosis
-
Sep 1, 2025, 07:35Dario Bongiovanni Presents Milestone Discovery on Reticulated Platelets at ESC Congress 2025
-
Sep 1, 2025, 07:19Felice Gragnano: Clopidogrel vs Aspirin for Secondary Prevention in Coronary Artery Disease – Meta-Analysis Shows Superior MACCE Protection
-
Sep 1, 2025, 07:18Wolfgang Miesbach: New Research Reveals Clonogenic Hepatocytes as the Key Drivers of Liver Growth and Gene Therapy Success
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Aug 18, 2025, 23:50Safe and Efficient Thrombectomy with Artix System: Clinical Insights from Neil Desai and Colleagues
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Sep 1, 2025, 08:09Wafik S. El-Deiry Opens Up on Recovery, Gratitude, and Book After Life-Changing Heart Surgery
-
Aug 31, 2025, 07:30Michael Albert: Being ‘Metabolically Healthy’ Doesn’t Eliminate Heart Disease Risk
-
Aug 31, 2025, 07:15Should 12-Month DAPT Be the Default After ACS? Mattia Galli Applauds Marco Valgimigli’s Talk
-
Aug 31, 2025, 07:10Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
-
Aug 30, 2025, 14:45Gordon’s Journey: 60 Years of Life After DVT Managed with Warfarin